At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Tofacitinibdrug
Likely dose
Tofacitinib 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of Tofacitinib in Patients With Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
In Brief
A clinical study evaluating Tofacitinib for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The goal of this study is to evaluate the effect of tofacitinib in patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The primary outcome of the study is the time to complete re-epithelialization. The secondary outcomes are to determine mortality, length of hospitalization, adverse events, the time to beginning of epithelization, the time to halting of progression of SJS/TEN, ocular complications, and infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartAug 2022
First PostedJun 2024
Primary CompletionJun 2025
TodayJul 2026
First PostedJun 25, 2024
Enrollment StartAug 1, 2022
Primary CompletionJun 20, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 2.0 years ago
Interventions
Tofacitinibdrug
Dosage/Frequency: 5mg - 10mg, oral, twice daily